Targeting immune checkpoints in non small cell lung cancer
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 40, 46-50
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- BARD1: An independent predictor of survival in non‐small cell lung cancerInternational Journal of Cancer, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Interaction of human PD-L1 and B7-1Molecular Immunology, 2008
- Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II studyCancer Chemotherapy and Pharmacology, 2007
- Checkpoint Blockade in Cancer Immunotherapy2006
- Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosisInternational Journal of Cancer, 2005
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002